



## Stoma Appliance Scheme (SAS) - Group 9 Review

### Submission Form for Comments on the Group 9 Review Discussion Paper

DETAILS FOR PUBLICATION	
Individual, Group or Organisation's name for publication on the website	AusBiotech
CONTACT DETAILS	
We need to collect your contact details should further information or clarification be required on your submission. Contents of your submission may be included in subsequent publications. Please provide at least one contact address. If you are making a submission for a group or organisation, please provide contact information for one member of your group or organisation.	
Title	Dr
First Name	Anna
Surname/Family Name	Lavelle
Postal Address	Suite 4, Level 4, 627 Chapel Street, South Yarra. VIC 3141
Email Address	alavelle@ausbiotech.org
Telephone Number	(03) 9828 1400
ANONYMITY	
<input type="checkbox"/> Please tick this box if you want your <b>submission to be treated as anonymous</b> and you do not consent to having your name or the name of your group/organisation be published on the internet with your submission.	
INTERNET PUBLICATION	
<input type="checkbox"/> Please tick this box if you wish for your <b>entire submission to remain confidential</b> and do not consent to having your submission published on the internet.	
<input type="checkbox"/> Please tick this box if you wish for <b>only part/s of your submission to remain confidential</b> and not be published on the website. Please outline the confidential section/s clearly or provide the confidential part/s of your submission as a separate document.	
If you wish the entire <u>or</u> part/s of your submission to remain confidential, please <b>outline the reasons for your request</b> , e.g. commercial in confidence.	
THIRD PARTY PERSONAL INFORMATION	
<input type="checkbox"/> Please tick this box if your <b>submission contains personal information</b> of third party individuals.	
EVIDENCE OF CONSENT	
You <b>should not include personal information</b> about a third party <b>unless</b> you are <b>able to provide evidence of written consent</b> .	
<input type="checkbox"/> Please tick this box if you have attached <b>evidence of written consent</b> .	



***Summary of key points for SPAP's consideration:***

AusBiotech's Stoma Industry Group (SIG) recognises the importance of the review of Group 9 accessory products under the SAS to manage the growth in utilisation of the category. The SIG:

1. Supports the conclusions of the Expert Advisory Group (EAG) that a clinical authorisation process is a viable mechanism for the management of Group 9 product utilisation. Clinical authorisation of the use of Group 9 Accessory Products will minimise inappropriate or inefficient product utilisation while also continuing to deliver optimal clinical outcomes currently achieved by the SAS.
2. Propose the establishment of a stakeholder working group, with representatives from the Australian Council of Stoma Associations (ACSA), the Australian Association of Stomal Therapy Nurses (AASTN), SIG and the Federal Government, to devise the most appropriate process for implementation of a clinical authorisation process for ostomates.
3. Cautions the Department against implementation of mechanisms that do not include a needs assessment by a suitably qualified healthcare professional. Savings from such measures may be outweighed by the real potential for negative clinical outcomes for ostomates who rely on availability of accessory products for the management of their stoma. There is also a potential that short term financial gains may be negated by an increase in the cost of the remainder of the scheme.

***Introduction***

AusBiotech is a well-connected network of over 3,000 members in the life sciences, working on behalf of members for more than 25 years to provide representation to promote the global growth of Australian biotechnology. The SIG is the national industry group representing the stoma industry sector in Australia. SIG members include Ainscorp, Coloplast, Convatec, Liberty Medical and Omnigon who together supply over 98% of product supplied by the SAS. The SIG would like to thank the Department of Health for the opportunity to comment on the findings of the Group 9 Literature Review and Discussion Paper.

SIG recognises the importance of the review of Group 9 accessory products under the SAS to manage the growth in utilisation of the category. Group 9 products represent a significant proportion of the scheme utilisation, which makes it important for the sustainability of the scheme to ensure their efficient usage, while also maintaining optimal clinical outcomes for ostomates. We also note, however, that the EAG indicate that "changing demographic and health status of the population" and changes to surgical techniques may provide context for increased product usage, indicating that the growth may be warranted for the delivery of appropriate standards of stoma care. (Australian Government, 2014, p. 6)

SIG also recognises the literature review completed by the University of Tasmania and its findings. Importantly, we note that this review found "firm conclusions about the effectiveness and cost-effectiveness of Group 9 products cannot be drawn from the available literature." (University of Tasmania, 2014, p. 5). With such a conclusion, it is difficult to make decisions on many direct actions to curb the growth of Group 9 product utilisation without potentially negative impacts on the level of quality stoma care for Australian ostomates.

In order to achieve the Government's goal of controlling growth of accessory usage, the following mechanisms are available:

1. Clinical authority before initiation of accessory products;
2. Removal of current product listings, either singularly or by sub-group;



3. Price reductions of current products;
4. Adjustment of maximum quantities available of products under the scheme; and/or
5. Limitation of new product introductions.

SIG suggests that implementation of a clinical authorisation process, as proposed by the EAG, is a viable approach to control the growth of the utilisation of Group 9 products. The implementation of an authorisation process would require a stakeholder working group to ensure a smooth transition period and maintenance of optimal clinical outcomes.

Any benefits of other proposed mechanisms, such as short term financial savings, may be outweighed by the real potential for negative clinical outcomes for ostomates who rely on availability of accessory products for the management of their stoma. There is also a potential that short term financial gains may be negated by an increase in the cost of the remainder of the scheme.

### ***Evaluation of options for management of Group 9 product utilisation***

Each of the potential mechanisms available to address the growth of the Group 9 product utilisation has been considered by the members of SIG and we have prepared the following suggestions.

#### ***Clinical authority before initiation of new accessory products***

The lack of evidence available to assess the effectiveness of accessories makes it very difficult to apply any broad changes to the scheme through mechanisms that do not include a needs assessment by a suitably qualified healthcare professional (HCP). It could be concluded that changes using the other suggested mechanisms have as much potential to lead to negative outcomes as they do positive.

It is also recognised that multiple clinical factors may impact the requirement for appropriate accessory use by ostomates, some of which are discussed by the EAG in the Group 9 Discussion paper. (Australian Government, 2014, p. 6)

In consideration of these issues, SIG agrees with the recommendation of the EAG that clinical assessment and authorisation of accessory use by a HCP is a viable mechanism to address the increasing use of accessory products on the scheme.

Through the application of an authority process, the objectives of the review will be achieved by:

- Removing the ability for ostomates to add accessory items to their association order without any clinical consultation;
- Making the HCP consider the appropriateness of accessory's use through an authorisation process. Normal buying behaviour will naturally curtail the use of accessories to some degree.
- It will limit patients ordering their entire allocation of a product that may not be suitable by first making sure that the product works.
- The range of product choices will remain to ensure the HCP has the ability to attain the best clinical outcomes for all ostomates based on their specific circumstances.



### ***Removal of current product listings***

The EAG consulted in the preparation of the Government’s discussion paper (Australian Government, 2014, pp. 7-12) recognised that products listed in each sub group of Group 9 serve some clinical purpose for ostomates, depending on their circumstances and condition. It is also the view of the EAG that, “stoma assessment and care is complex and multifaceted, taking into account the patient’s physical condition, ability to self-manage, psychosocial factors and availability of support” (Australian Government, 2014, p. 7). With so many variables, HCPs and ostomates need a wide variety of product options to ensure optimal clinical outcomes and quality of life.

It is therefore the conclusion of SIG that the removal of current products available in Group 9 will limit the clinical options available to address the stoma requirements of the ostomates. It is also recognised however that the appropriate use of products in Group 9 is paramount and clinical guidance is required for ostomates.

We also recognise that removal of products from Group 9 will not address the primary goal of government to reduce growth of accessories usage, with any financial benefit being only in the short term.

### ***Price reductions of current products***

Due to factors such as exchange rates, supply chain costs and different market conditions it is difficult to make price comparisons between stoma appliances in Australia and overseas markets. We note the analysis conducted by the University of Tasmania to identify price comparators in other markets uses comparators from varying markets (University of Tasmania, 2014, pp. 26-35). We find that this information is used selectively when estimating potential savings of \$1.9m on products with a lower comparator pricing (University of Tasmania, 2014, p. 41). By contrast, if this data is used as a full price comparison across the range of products the net impact shows that the government is currently benefitting from a saving to the scheme of \$4.8m under the current pricing model (See Appendix 1: Comparator price analysis).

SIG would also like to note that price reductions would only have a short term impact on the costs of scheme and not address the issue of growth through potentially inappropriate or excessive use of accessories.

### ***Adjustment of maximum quantities available of products under the scheme***

The reduction of maximum quantities of Group 9 products may lead to diminished clinical outcomes for some ostomates due to their specific clinical needs. While it is noted in the discussion paper that: “Anecdotal information from the advisory group suggested that some patients are stockpiling excess products,” (Australian Government, 2014, p. 6) it would seem inappropriate to base a decision to broadly reduce quantities on anecdotal evidence alone. By contrast, Conclusion 3 of the University of Tasmania’s literature review states: “Limits to product quantities specified in the SAS are consistent with limits in international schemes.” (University of Tasmania, 2014, p. 7)

We conclude from this information that broad reduction in maximum quantities may not be appropriate; however greater clinical input into ostomates order quantities may be warranted in some circumstances.



### ***Limitation of new product introductions***

Product innovation is the cornerstone of improved clinical practices in stoma care and subject to significant ongoing investment by all stoma product manufacturers. The driver of innovation is through feedback from clinical experts around the world who demand product innovation to improve the delivery of stoma care.

SIG notes Conclusion 1 of the literature review, which states: “A requirement for level 2 evidence or higher for the listing of new accessory products on the Group 9 SAS Schedule would enable a more detailed assessment of the effectiveness and cost-effectiveness of Group 9 accessories to be performed into the future.” (University of Tasmania, 2014, p. 7) While this may be a worthwhile goal, it has practical limitations due to the “paucity of published studies of the effectiveness of stoma accessories.” (University of Tasmania, 2014, p. 6) While stoma product suppliers may wish to develop their own clinical studies, it was also noted by the University of Tasmania that industry sponsored studies are prone to bias and therefore discounted.

As a consequence, any additional requirement for higher levels of clinical evidence would effectively act as a barrier to entry for new product innovations. The result of this would be limited or delayed access to new products and potentially lead to lower quality of care for Australian ostomates. The SIG contests the requirement of such high levels of clinical data for Class 1 products and feels that market forces will drive demand for stoma products based on their performance.

### ***Stoma Industry Group recommendations***

On consideration of the information presented in the literature review of the University of Tasmania and the EAP in the Group 9 Discussion Paper, combined with the joint experience and perspectives of SIG members, we support the implementation of an authority mechanism on Group 9 Accessories.

In recognition that the practical application of such a scheme will need to be considered carefully to ensure efficient implementation, we further recommend the establishment of a working group with members from all stakeholders, including the AASTN, ACSA, the SIG and the SAS.

This working group may consider implementation elements such as:

**1. *Authorisation administrative process***

Consideration would need to be given to level of access to HCPs to gain authorities, particularly for ostomates from remote and regional Australia or those with limited mobility.

**2. *Application and scope of authorisation***

In order to maintain a controlled implementation of an authorisation process, we would propose a “grandfather” arrangement, where authorisation is only required for new ostomate commencements.

**3. *Local clinical usage research***

To improve decision making in the management of accessories on the scheme, the working group may consider conducting Australian-based research into the usage and outcomes of Group 9 products. This may assist in gathering a more definitive understanding of product effectiveness and clinical impact to guide the implementation of an appropriate authorisation process.

**4. *Product categorisation***

The working group may consider re-categorisation of the current Group 9 products to help streamline any authorisation process by the application of different requirements for each



category, specifically in elements such as validity periods of authorisation, quantities authorised, and so on.

### ***Conclusion***

The members of the SIG consider themselves important stakeholders in the delivery of world class stoma care for Australia's 41,000 plus ostomates. As such, the sustainability of the SAS is considered paramount to ensure the ongoing maintenance of quality of life for those managing this challenging medical condition.

SIG members have willingly worked with all stakeholders of the scheme since its inception to ensure the availability of world leading products through an efficient distribution and reimbursement system. Once again, we wish to work with the relevant stakeholders to ensure that efficiencies are achieved in the provision of Group 9 products, while minimising the risk of diminished quality of life for ostomates.

After careful consideration and consultation, we would support the introduction of clinical authorisation as a viable mechanism in controlling the growth of Group 9 product usage, while also ensuring the best clinical outcomes for ostomates. To ensure the smooth implementation of an authorisation process, SIG recommends the formation of a working group of all relevant stakeholders to develop a suitable administrative process.

### ***Bibliography***

1. Australian Government (2014), Discussion paper – Review of Group 9 accessory products under the Stoma Appliance Scheme.
2. University of Tasmania (2014), A literature review and background analysis to support the review of accessory products listed under Group 9 of the Stoma Appliance Scheme Schedule.



**Appendix 1: Comparator price analysis**

The following data is sourced from the University of Tasmania Literature Review and background analysis to support the review of accessory products listed under Group 9 of the Stoma Appliance Scheme Schedule.

Sub Group	Brand Name	SAS Pack Price (AUD)	Comparator (AUD)	2012/13 costs (AUD)	Relative cost to comparator	Net pricing impact on scheme
a	Ainscorp Salts Secu Plast Hydro	\$43.74	\$21.96	\$608,423	\$305,463.40	-\$302,959.60
a	Ainscorp Salts SecuPlast Hydro Aloe	\$43.74	\$23.79	\$388,577	\$211,345.38	-\$177,231.62
a	Coloplast Brava Elastic Tape	\$29.16	\$23.39	\$259,611	\$208,240.78	-\$51,370.22
a	Coloplast Brava Protective Sheet	\$72.90	\$96.66	\$137,112	\$181,800.36	\$44,688.36
a	Coloplast Protective Sheet Dispenser	\$47.14	\$201.70	\$13,812	\$59,098.01	\$45,286.01
a	Convatec Skin Barrier	\$14.38	\$21.91	\$52,087	\$79,362.04	\$27,275.04
a	Hollister Flextend	\$14.38	\$14.38	\$4,990	\$4,990.00	\$0.00
a	Hollister Hollihesive	\$14.38	\$22.15	\$3,466	\$5,338.80	\$1,872.80
a	Omnigon Welland Hydroframe	\$28.56	\$42.74	\$985,877	\$1,475,363.55	\$489,486.55
a	Omnigon Welland Hydroframe Mini	\$42.84	\$18.29	\$4,327	\$1,847.36	-\$2,479.64
b	Ainscorp Salts Adjust. Ostomy Belt	\$5.98	\$13.56	\$3,654	\$8,285.66	\$4,631.66
b	Coloplast Belt	\$5.98	n/a	\$3,211	\$0.00	\$0.00
b	Coloplast Brava Belt	\$5.98	\$12.16	\$22,234	\$45,211.61	\$22,977.61
b	ConvaTec Belt	\$5.98	\$6.33	\$8,593	\$9,095.93	\$502.93
b	Dansac Beige Ostomy Belt	\$5.98	13.41	\$11,799	\$26,458.96	\$14,659.96
b	Hollister Adapt	\$5.98	\$14.30	\$32,872	\$78,606.96	\$45,734.96
b	Omnigon Adjustable Belt	\$5.98	n/a	\$9,329	\$0.00	\$0.00
b	Omnigon Braun Stomacare Belt	\$5.98	13.89	\$1,429	\$3,319.20	\$1,890.20
b	Omnigon Flair Belt Pack*	\$5.98	\$13.41	\$2,512	\$5,633.10	\$3,121.10
c	Hollister Clamps	\$46.10	\$38.90	\$1,346	\$1,135.78	-\$210.22
c	ConvaTec Clips	\$23.05	\$44.20	\$373	\$715.25	\$342.25
c	Coloplast Alterna Slimline	\$46.10	\$39.43	\$537	\$459.30	-\$77.70
c	Hollister ModermaFlex	\$2.30	\$2.30	\$243	\$243.00	\$0.00
c	Dansac Nova Drainable Clamp	\$2.30	n/a	\$156	\$0.00	\$0.00
d	Ainscorp Salts Wipe Away	\$14.34	\$16.54	\$77,386.10	\$89,258.44	\$11,872.34
d	Coloplast Brava No Sting Adhesive Remover Wipes	\$11.94	\$26.97	\$37,214.96	\$84,060.93	\$46,845.97
d	Coloplast Brava No Sting Adhesive Remover Spray	\$10.23	\$16.27	\$49,144.92	\$78,161.08	\$29,016.16
d	Coloplast Comfeel (2 products)	\$8.35	\$32.16	\$135,458.58	\$521,718.32	\$386,259.74
d	ConvaTec ConvaCare	\$32.00	\$33.10	\$541,587.52	\$560,204.59	\$18,617.07
d	Dansac Skin Lotion	\$8.35	\$32.22	\$403,586.82	\$1,557,313.45	\$1,153,726.63
d	Dansac Skin Lotion Wipes	\$23.90	\$27.60	\$454,412.61	\$524,761.01	\$70,348.40
d	Hollister Cleanser	\$8.35	\$8.35	\$8,792.55	\$8,792.55	\$0.00
d	Hollister Universal	\$16.00	\$24.95	\$145,500.80	\$226,890.31	\$81,389.51
d	Omnigon Eakin Release Wipes	\$11.94	n/a	\$12,895.20	\$0.00	\$0.00
d	Omnigon Welland	\$23.90	\$43.09	\$1,122,607.39	\$2,023,981.27	\$901,373.88
d	Omnigon Welland Adhesive Remover Spray	\$10.23	n/a	\$9,176.31	\$0.00	\$0.00
d	Smith & Nephew Remove	\$16.00	\$44.00	\$137,136.00	\$377,124.00	\$239,988.00



**Australian Government**  
**Department of Health**

Sub Group	Brand Name	SAS Pack Price (AUD)	Comparator (AUD)	2012/13 costs (AUD)	Relative cost to comparator	Net pricing impact on scheme
d	Smith & Nephew SECURA	\$8.35	n/a	\$567.80	\$0.00	\$0.00
e	ConvaTec Sur-Fit Plus	\$9.46	n/a	\$11,598	\$0.00	\$0.00
f	3M Cavilon Durable	\$5.75	\$7.32	\$2,105	\$2,679.76	\$574.76
f	Calmoseptine Oint 20g	\$4.71	\$5.20	\$871	\$961.61	\$90.61
f	Calmoseptine Oint 75g	\$7.68	\$11.30	\$8,387	\$12,340.25	\$3,953.25
f	Coloplast Comfeel	\$7.92	\$8.85	\$10,288	\$11,496.06	\$1,208.06
f	Coloplast Conveen Critic	\$7.85	\$19.60	\$3,721	\$9,290.65	\$5,569.65
f	ConvaTec Orabase	\$8.74	\$15.90	\$34,444	\$62,661.28	\$28,217.28
f	Dansac Ostomy	\$8.74	n/a	\$15,888	\$0.00	\$0.00
f	Hollister Skin Conditioning Cream	\$7.92	\$7.92	\$21,859	\$21,859.00	\$0.00
f	Smith & Nephew Uni Derm	\$7.92	n/a	\$10,058	\$0.00	\$0.00
f	Sudocrem Healing Cream	\$5.54	\$8.90	\$24,520	\$39,391.34	\$14,871.34
g	Ainscorp Salts No-Roma	\$8.13	\$5.15	\$4,740	\$3,002.58	-\$1,737.42
g	Dansac Nodor 'S'	\$4.05	\$8.02	\$73,698	\$145,940.24	\$72,242.24
g	Dansac Windless	\$11.31	n/a	\$133,718	\$0.00	\$0.00
g	Hollister Adapt	\$9.91	\$17.13	\$209,226	\$361,659.07	\$152,433.07
g	Hollister M9 Drop	\$8.13	\$8.13	\$13,301	\$13,301.00	\$0.00
g	Hos-Toma Lube	\$9.91	n/a	\$10,406	\$0.00	\$0.00
g	Hos-Toma No Smell	\$4.05	n/a	\$25,879	\$0.00	\$0.00
g	Hos-Toma No-Gas	\$11.31	n/a	\$12,565	\$0.00	\$0.00
g	Laza Odorgon	\$4.05	n/a	\$16	\$0.00	\$0.00
g	Smith & Nephew Banish	\$3.97	n/a	\$7,142	\$0.00	\$0.00
g	Wooltec Wooltec	\$4.05	n/a	\$8,294	\$0.00	\$0.00
h	Ainscorp Salts Simplicity Abdominal support	\$60.00	\$22.93	\$371,400	\$141,936.70	-\$229,463.30
h	Omnigon Diamond Plus	\$60.00	n/a	\$256,373	\$0.00	\$0.00
h	Omnigon Kool-Knit	\$45.15	n/a	\$140,146	\$0.00	\$0.00
h	Omnigon Mens support Boxers. Hernia support garment,	\$60.00	\$31.28	\$1,380	\$719.44	-\$660.56
h	Omnigon Stoma Support Belt	\$71.01	\$83.57	\$106,160	\$124,937.21	\$18,777.21
h	Omnigon Support Briefs for Her	\$60.00	\$31.28	\$42,120	\$21,958.56	-\$20,161.44
h	Omnigon Support Pants for Him	\$60.00	\$31.28	\$99,360	\$51,799.68	-\$47,560.32
h	Omnigon Total Control	\$71.01	n/a	\$63,270	\$0.00	\$0.00
h	Statina Healthcare Corsinel Abdominal support	\$120.02	\$155.00	\$125,421	\$161,975.13	\$36,554.13
h	Sutherland Medical Abdominal Binder	\$45.15	n/a	\$271	\$0.00	\$0.00
i	Ainscorp Salts Night Drainage Bag	\$2.19	n/a	\$6,301	\$0.00	\$0.00
i	Coloplast S3 extended term -urostomy night drainage bag	\$2.19	\$2.50	\$39,845	\$45,485.16	\$5,640.16
i	Coloplast Simpla S4 - urostomy night drainage bag	\$2.19	\$6.40	\$73,361	\$214,388.31	\$141,027.31
i	Hollister T-Tap Night Drainage Collector	\$65.70	\$65.70	\$28	\$28.00	\$0.00
i	Hollister Night Drainage Collector -	\$2.19	\$2.19	\$122,672	\$122,672.00	\$0.00
i	Omnigon Braun Urimed Bag 2L	\$21.90	n/a	\$1,229	\$0.00	\$0.00
i	Unomedical A4 Drainage Bag	\$2.19	n/a	\$45,291	\$0.00	\$0.00





**Australian Government**  
**Department of Health**

Sub Group	Brand Name	SAS Pack Price (AUD)	Comparator (AUD)	2012/13 costs (AUD)	Relative cost to comparator	Net pricing impact on scheme
i	Unomedical Night Drainage Bag	\$2.19	n/a	\$9,813	\$0.00	\$0.00
j	Ainscorp Salts Stoma Paste	\$11.28	\$12.80	\$8,448	\$9,586.38	\$1,138.38
j	Coloplast Brava Strip Paste	\$11.28	\$14.35	\$21,781	\$27,708.98	\$5,927.98
j	Coloplast Paste Tube	\$11.28	\$11.59	\$21,307	\$21,892.56	\$585.56
j	ConvaTec Paste	\$11.28	\$13.73	\$325,112	\$395,725.87	\$70,613.87
j	ConvaTec Powder	\$8.70	\$18.10	\$201,805	\$419,847.18	\$218,042.18
j	Dansac Soft Paste	\$11.28	\$6.62	\$38,216	\$22,428.18	-\$15,787.82
j	Hollister Adapt Paste	\$11.28	\$7.10	\$72,214	\$45,453.85	-\$26,760.15
j	Hollister Karaya Paste	\$11.28	\$15.51	\$6,023	\$8,281.63	\$2,258.63
j	Hollister Premium Powder	\$8.70	\$4.73	\$46,840	\$25,465.89	-\$21,374.11
k	3M Cavilon	\$31.95	\$36.97	\$1,351,712	\$1,564,093.67	\$212,381.67
k	3M No Sting	\$15.31	\$12.24	\$22,812	\$18,237.68	-\$4,574.32
k	Ainscorp Salts Peri-Prep Sensitive	\$31.95	\$28.47	\$53,484	\$47,658.51	-\$5,825.49
k	Coloplast Brava No Sting Skin Barrier Spray	\$26.25	\$21.12	\$11,970	\$9,630.72	-\$2,339.28
k	Coloplast Brava No Sting Skin Barrier Wipes	\$31.95	\$40.11	\$48,760	\$61,213.26	\$12,453.26
k	ConvaTec ConvaCare	\$29.00	\$33.10	\$323,249	\$368,949.72	\$45,700.72
k	Hollister Skin Gel	\$14.50	\$25.54	\$40,426	\$71,205.52	\$30,779.52
k	Omnigon WBF Barrier Film	\$31.95	\$49.50	\$1,113,319	\$1,724,860.42	\$611,541.42
k	Smith & Nephew SECURA No-Sting Barrier Film	\$52.10	\$41.78	\$470	\$376.90	-\$93.10
k	Smith & Nephew Skin Prep	\$14.50	n/a	\$49,957	\$0.00	\$0.00
k	Smith & Nephew Skin Prep Aerosol	\$8.45	\$18.64	\$1,470	\$3,242.70	\$1,772.70
k	Smith and Nephew Skin Prep Spray	\$15.31	\$10.25	\$31	\$20.75	-\$10.25
l	Ainscorp Salts Dermacol	\$135.96	\$100.22	\$438,471	\$323,209.50	-\$115,261.50
l	Ainscorp Salts Secuplast mouldable	\$45.31	\$41.44	\$583,595	\$533,749.21	-\$49,845.79
l	AMSL Medicina Ace	\$104.19	n/a	\$37,925	\$0.00	\$0.00
l	Coloplast Brava Mouldable Ring	\$135.93	\$104.24	\$176,392	\$135,268.90	-\$41,123.10
l	Dansac GX-TRA	\$135.96	\$77.94	\$1,050,291	\$602,086.50	-\$448,204.50
l	Dansac NovaLife	\$135.96	\$122.14	\$166,242	\$149,343.91	-\$16,898.09
l	Hollister Adapt barrier seals	\$45.31	\$32.27	\$1,438,103	\$1,024,223.88	-\$413,879.12
l	Hollister Oval Convex Barrier Rings	\$45.31	\$34.22	\$38,649	\$29,189.34	-\$9,459.66
l	Omnigon Cohesive Seal	\$135.96	\$204.66	\$1,859,587	\$2,799,228.27	\$939,641.27
l	Omnigon Cohesive Slims	\$135.96	\$171.45	\$1,936,433	\$2,441,905.25	\$505,472.25
m	Coloplast Cathstrap	\$4.78	\$13.38	\$7,184	\$20,109.19	\$12,925.19
m	Coloplast Filtrodor	\$17.95	\$42.03	\$8,616	\$20,174.40	\$11,558.40
m	Ebos Group Vernagel	\$74.70	\$137.20	\$22,299	\$40,956.13	\$18,657.13
m	Hollister Silicone Adhesive Spray	\$35.65	\$30.73	\$8,271	\$7,129.53	-\$1,141.47
m	Omnigon Eakin Perform	\$49.80	n/a	\$176,666	\$0.00	\$0.00

**Net cost impact on scheme using all comparator prices \$4,818,026.54**